{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:02:08Z","timestamp":1791158528545,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Canada"},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim Canada"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236580","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:40:09Z","timestamp":1596649209000},"page":"e0236580","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Molecular profiling of non-small cell lung cancer"],"prefix":"10.1371","volume":"15","author":[{"given":"Marika L.","family":"Forsythe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Alwithenani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Bethune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-8673","authenticated-orcid":true,"given":"Arik","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Flowerdew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenda","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Henteleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"MacNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Morzycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelaine","family":"Plourde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-4081","authenticated-orcid":true,"given":"Zhaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"pone.0236580.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung Cancer Statistics","volume":"893","author":"LA Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"9760","key":"pone.0236580.ref002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","article-title":"Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995\u20132007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data","volume":"377","author":"MP Coleman","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"pone.0236580.ref003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/0975-2870.160783","article-title":"Correlation of age and gender with different histological subtypes of primary lung cancer","volume":"8","author":"R Afrose","year":"2015","journal-title":"Med J DY Patil Univ"},{"issue":"3","key":"pone.0236580.ref004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/modpathol.3800055","article-title":"Benign mimickers of prostatic adenocarcinoma","volume":"17","author":"JR Srigley","year":"2004","journal-title":"Modern Pathology"},{"key":"pone.0236580.ref005","volume-title":"Robbins and Cotran Pathologic Basis of Disease","author":"V Kumar","year":"2010","edition":"8"},{"issue":"18","key":"pone.0236580.ref006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.21037\/atm.2017.06.72","article-title":"Relevance of genetic alterations in squamous and small cell lung cancer","volume":"5","author":"JK Sabari","year":"2017","journal-title":"Ann Transl Med"},{"issue":"9","key":"pone.0236580.ref007","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"WD Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"pone.0236580.ref008","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/annonc\/mdr489","article-title":"Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice","volume":"22","author":"LV Sequist","year":"2011","journal-title":"Annals of Oncology"},{"issue":"3","key":"pone.0236580.ref009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"C Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"pone.0236580.ref010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib","volume":"364","author":"VD Cataldo","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0236580.ref011","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"CK Lee","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"pone.0236580.ref012","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"AT Shaw","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"25","key":"pone.0236580.ref013","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"468","author":"AT Shaw","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0236580.ref014","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations\u2014review","volume":"4","author":"EL Stewart","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"pone.0236580.ref015","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"T Kosaka","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"21","key":"pone.0236580.ref016","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor\u2013Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors","volume":"12","author":"MN Balak","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0236580.ref017","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"S Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0236580.ref018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"J-C Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0236580.ref019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"SS Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0236580.ref020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"TS Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"34","key":"pone.0236580.ref021","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer","volume":"34","author":"SM Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0236580.ref022","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"DW Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"26","key":"pone.0236580.ref023","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials","volume":"36","author":"DR Camidge","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0236580.ref024","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"S Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0236580.ref025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"K Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0236580.ref026","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"D Planchard","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0236580.ref027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/74215","article-title":"Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse","volume":"24","author":"K Lindblad-Toh","year":"2002","journal-title":"Nat Genet"},{"issue":"12","key":"pone.0236580.ref028","first-page":"2441","article-title":"Application of SNaPshot multiplex assays for simultaneous multigene mutation screening in patients with idiopathic sensorineural hearing impairment","volume":"119","author":"CC Wu","year":"2009","journal-title":"Laryngoscope"},{"issue":"4","key":"pone.0236580.ref029","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2353\/jmoldx.2010.090222","article-title":"Single PCR Multiplex SNaPshot Reaction for Detection of Eleven Blood Group Nucleotide Polymorphisms","volume":"12","author":"JD Cristofaro","year":"2010","journal-title":"J Mol Diagn"},{"issue":"2","key":"pone.0236580.ref030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.27730","article-title":"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma","volume":"119","author":"ML Johnson","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"pone.0236580.ref031","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cllc.2013.05.002","article-title":"Determinants of survival in advanced non\u2014small-cell lung cancer in the era of targeted therapies","volume":"14","author":"J Bauml","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"7417","key":"pone.0236580.ref032","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"The Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature"},{"issue":"2","key":"pone.0236580.ref033","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2006.07.006","article-title":"PIK3CA mutation status in Japanese lung cancer patients","volume":"54","author":"O Kawano","year":"2006","journal-title":"Lung Cancer"},{"issue":"12","key":"pone.0236580.ref034","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1349-7006.2006.00343.x","article-title":"PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma","volume":"97","author":"K Kozaki","year":"2006","journal-title":"Cancer Science"},{"issue":"23","key":"pone.0236580.ref035","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/jnci\/91.23.2032","article-title":"Implications and prognostic value of K-ras mutation for early-stage lung cancer in women","volume":"91","author":"HH Nelson","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"pone.0236580.ref036","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"PMK Westcott","year":"2013","journal-title":"Chin J Cancer"},{"issue":"5","key":"pone.0236580.ref037","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"H Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"pone.0236580.ref038","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","author":"AF Gazdar","year":"2009","journal-title":"Oncogene"},{"issue":"16","key":"pone.0236580.ref039","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumour registry of clinical trials","volume":"15","author":"DM Jackman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"pone.0236580.ref040","unstructured":"Reddi HV. Mutations in the EGFR Pathway. AACC. October 1, 2013. https:\/\/www.aacc.org\/publications\/cln\/articles\/2013\/october\/egfr-mutations."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:40:57Z","timestamp":1596649257000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236580"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"De Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236580","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]}}}